Overview
This is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease.
The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.
Eligibility
Inclusion Criteria:
- Age ≥ 18 years.
- Histologically or cytologically confirmed diagnosis of pancreatic cancer.
- Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.
- Underwent surgical treatment for pancreatic cancer at a participating center of this study.
Exclusion Criteria:
- Age \< 18 years (minors).
- Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;
- patients unable to comply with follow-up or provide informed consent.
- Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.
